Related Experiment Video
Updated: Nov 11, 2025

10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.4K
GOECP/SEOR radiotherapy guidelines for small-cell lung cancer.
Felipe Couñago1, Carolina de la Pinta2, Susana Gonzalo3
1Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea de Madrid, Madrid 28223, Madrid, Spain. fcounago@gmail.com.
World Journal of Clinical Oncology
|March 26, 2021
Summary
Small cell lung cancer (SCLC) treatment guidelines emphasize chemotherapy and radiotherapy. Combining these modalities, including prophylactic cranial irradiation, significantly improves survival rates for SCLC patients.
Area of Science:
- Oncology
- Radiation Oncology
Background:
- Small cell lung cancer (SCLC) constitutes about 20% of all lung cancer diagnoses.
- Chemotherapy (Ch) is the primary treatment, but radiotherapy significantly enhances overall survival (OS).
Purpose of the Study:
- To present updated clinical guidelines for the diagnosis, planning, and treatment of SCLC.
- To offer a comprehensive review for radiation oncologists and clinicians.
Main Methods:
- Development of guidelines by Spanish radiation oncologists.
- Emphasis on treatment fields, radiation techniques, fractionation, and timing of Ch and radiotherapy.
- Review of prophylactic cranial irradiation and reirradiation indications.
Main Results:
- Radiotherapy addition improves OS in both non-metastatic and metastatic SCLC patients responding to Ch.
- Prophylactic cranial irradiation reduces brain metastases and improves OS.
- 5-year OS rates are over 30% for limited-stage and less than 5% for extensive-stage SCLC.
Conclusions:
- Guidelines provide a current review of SCLC management, integrating chemotherapy and radiotherapy.
- Optimal timing and techniques for radiation are crucial for improving patient outcomes.
- Reirradiation strategies for local recurrence are also discussed.
Keywords:
Brain metastasesChemotherapyHyperfractionated radiation therapyProphylactic brain irradiationReirradiationSmall cell lung cancerMore Related Videos
Related Concept Videos
Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

